Jane Street’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Jane Street’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-146,340	Closed	-$1.47M	–	10474
2022 Q4	$1.47M	Buy	146,340 +6,293	+4%	+$63K	﹤0.01%	4345
2022 Q3	$1.39M	Buy	140,047 +2,544	+2%	+$25.2K	﹤0.01%	4839
2022 Q2	$1.34M	Buy	137,503 +400	+0.3%	+$3.94K	﹤0.01%	4929
2022 Q1	$1.35M	Sell	137,103 -4	-0%	-$40	﹤0.01%	5504
2021 Q4	$1.36M	Buy	137,107 +1	+0%	+$10	﹤0.01%	5289
2021 Q3	$1.36M	Buy	137,106 +2	+0%	+$20	﹤0.01%	5284
2021 Q2	$1.37M	Buy	137,104 +12,104	+10%	+$121K	﹤0.01%	5134
2021 Q1	$1.26M	Buy	+125,000	New	+$1.25M	﹤0.01%	5004

Jane Street's EBACU Position: Q1 2023 in Review

Jane Street sold out of European Biotech Acquisition Corp. Units (EBACU) in Q1 2023, closing a stake of 146,340 shares — an estimated $1.47M sold.

Jane Street first reported a position in EBACU in Q1 2021 and held it in 8 quarters. The position peaked at $1.47M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBACU as of Q1 2023.

Jane Street reported no remaining European Biotech Acquisition Corp. Units position as of Q1 2023 after selling out during the quarter.
Jane Street sold 146,340 European Biotech Acquisition Corp. Units shares in Q1 2023, an estimated $1.47M.
Jane Street first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 8 quarters.
Jane Street's European Biotech Acquisition Corp. Units position peaked at $1.47M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.